When Sigma-Aldrich announced a licensing agreement with St. Louis-based InGex last week, the chemical giant was not only sealing a deal to add an entirely new product line into its molecular biology tools portfolio, and sell more oligonucleotides and reagents from its website, it was also also taking an option on a platform with the potential to spin off new products to meet future market demands.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

NPR reports that Turkish high school students will no longer study evolution.

Researchers report they sequenced and identified plant species in an "al fresco" laboratory.

An Australian team searches for genetic alterations linked to depression in hopes of developing personalized treatments, the Sydney Morning Herald reports.

In PNAS this week: host contributors to typhoid fever risk, effects of obesity-related variants near TMEM18, and more.